USA flag logo/image

An Official Website of the United States Government

Autoantibody Profiling for Serological Detection of Head and Neck Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93555
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA139806
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
20/20 GENESYSTEMS, INC.
9430 Key West Ave. Suite 100 ROCKVILLE, MD 20850-6347
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Autoantibody Profiling for Serological Detection of Head and Neck Cancer
Agency: HHS
Contract: 1R43CA139806-01
Award Amount: $217,801.00
 

Abstract:

DESCRIPTION (provided by applicant): SBIR grant support is being sought by 20/20 GeneSystems, Inc. (20/20), a small biotech company, to help us advance what we believe will become the first blood test to be routinely employed to aid in the early detection of head and neck cancer. Despite recent advances in both diagnostic and therapeutic modalities, long-term prognosis for patients affected by advanced stage head and neck squamous cell carcinoma (HNSCC) remains dismal with 5-year survival less than 40%. Thi s grim prognosis is in distinct contrast to the more than 80% chance of cure for those patients who present with early stage cancer. Unfortunately, more than two-third of patients with HNSCC are diagnosed only after the disease is advanced. Failure to diag nose this cancer early is mainly attributed to the unavailability of a screening test for high risk patients as well as frequent misdiagnosis of early stage cancer by primary physicians. An autoantibody immunoassay for head and neck squamous cell carcinoma (HNSCC) is expected to become a novel non-invasive tool for early diagnosis. Our long term strategy, which would become the subject of a Phase II SBIR grant application should Phase I work be successful, is to develop a tobacco user's chip to screen for both HNSCC and lung cancer in one blood sample, because current and former smokers are at high risk for both diseases. The serological test should have a significant impact on the quality of medical care for persons at risk, particularly for over 20% of t he US population who are users of tobacco and/or alcohol products. PUBLIC HEALTH RELEVANCE: A blood test for early detection of head and neck cancer could provide a cost-effective screening approach when applied to presently known high risk groups, who are : users of tobacco and/or alcohol, the immune-compromised, and those with premalignant lesions. It would enable a viable strategy for reducing the severe mortality rate of this disease.

Principal Investigator:

Nada H. Khattar
2404536339
NKHATTAR@2020GENE.COM

Business Contact:

Jonathan Cohen
gtroy@202gene.com
Small Business Information at Submission:

20/20 GENESYSTEMS, INC.
9430 Key West Ave. Suite 100 ROCKVILLE, MD 20850

EIN/Tax ID: 522272107
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No